KPMG published a new survey of 107 pharma execs and their expectations as to how various factors will play out for their company and the industry in 2012. The 107 execs represented the following breakdown - 45% work for companies with annual revenues greater than $10 B, 36% with revenues between $1 B to $10 B, and the remaining 19% were with companies between $100 M and $1 B in sales.
The biggest concerns expressed by the executives were with increased regulations and increased FDA scrutiny. The executives also predicted that head counts would stabilize, that merger and acquisition activity would moderate and that capital spending would be decreased.
Where will new growth come from? 52% believe from their own pipelines, and 36% from alliance partners. Also, 34% saw growth coming from outside the US market, and 25% said the repeal fothe healthcare reform bill would spur growth. See Pharmalot above for the rest of survey specifics.
Posted by Bruce Lehr June 25th 2012.